Thomford N, Kellermann T, Biney R, Dixon C, Badu Nyarko S, Ateko R
Malar J. 2024; 23(1):125.
PMID: 38685044
PMC: 11059713.
DOI: 10.1186/s12936-024-04930-1.
Zhang W, Zhang Y, Wen C, Jiang X, Wang L
Planta Med. 2023; 89(13):1195-1203.
PMID: 37236224
PMC: 10575715.
DOI: 10.1055/a-2102-0648.
Altieri B, Sbiera S, Herterich S, De Francia S, Della Casa S, Calabrese A
Cancers (Basel). 2020; 12(2).
PMID: 32033200
PMC: 7072643.
DOI: 10.3390/cancers12020359.
Wang P, Neiner A, Kharasch E
Drug Metab Dispos. 2019; 47(10):1195-1205.
PMID: 31324697
PMC: 6756292.
DOI: 10.1124/dmd.119.086348.
Hedrich W, Hassan H, Wang H
Acta Pharm Sin B. 2016; 6(5):413-425.
PMID: 27709010
PMC: 5045548.
DOI: 10.1016/j.apsb.2016.07.016.
Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.
Pinillos F, Dandara C, Swart M, Strehlau R, Kuhn L, Patel F
BMC Infect Dis. 2016; 16:56.
PMID: 26831894
PMC: 4735961.
DOI: 10.1186/s12879-016-1381-x.
An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.
Swart M, Evans J, Skelton M, Castel S, Wiesner L, Smith P
Front Genet. 2016; 6:356.
PMID: 26779253
PMC: 4703773.
DOI: 10.3389/fgene.2015.00356.
PharmGKB summary: Efavirenz pathway, pharmacokinetics.
McDonagh E, Lau J, Alvarellos M, Altman R, Klein T
Pharmacogenet Genomics. 2015; 25(7):363-76.
PMID: 25966836
PMC: 4461466.
DOI: 10.1097/FPC.0000000000000145.
Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism.
Sukasem C, Manosuthi W, Koomdee N, Santon S, Jantararoungtong T, Prommas S
Infection. 2013; 42(3):469-74.
PMID: 24293076
DOI: 10.1007/s15010-013-0560-6.
Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.
Figueroa S, Gomez A, Martin A, Valverde Merino M, Hurle A, Sanchez M
Clin Drug Investig. 2010; 30(6):405-11.
PMID: 20441246
DOI: 10.1007/BF03256910.
Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.
Joy M, Frye R, Stubbert K, Brouwer K, Falk R, Kharasch E
J Clin Pharmacol. 2010; 50(6):714-20.
PMID: 20103693
PMC: 3614080.
DOI: 10.1177/0091270009353031.
Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation.
Fan L, Wang J, Jiang F, Tan Z, Chen Y, Li Q
Eur J Clin Pharmacol. 2008; 65(4):403-9.
PMID: 19066872
DOI: 10.1007/s00228-008-0594-3.
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.
Wang H, Tompkins L
Curr Drug Metab. 2008; 9(7):598-610.
PMID: 18781911
PMC: 2605793.
DOI: 10.2174/138920008785821710.
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
Kharasch E, Mitchell D, Coles R, Blanco R
Antimicrob Agents Chemother. 2008; 52(5):1663-9.
PMID: 18285471
PMC: 2346649.
DOI: 10.1128/AAC.01600-07.
Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.
Coles R, Kharasch E
Pharm Res. 2008; 25(6):1405-11.
PMID: 18219560
PMC: 3596877.
DOI: 10.1007/s11095-008-9535-1.
